Tarpeyo Now Available to Reduce Proteinuria in Primary IgA Nephropathy
To help patients gain access to treatment, Calliditas Therapeutics has launched a patient support program called Tarpeyo Touchpoints.
All articles by Brian Park, PharmD
Long-Term Cardiovascular Safety Data Announced for Linagliptin
Results showed non-inferiority for linagliptin vs glimepiride in meeting its primary endpoint of time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke.
USPSTF Recommends PrEP for HIV Prevention in Individuals at High Risk
According to a final recommendation statement released by the US Preventive Services Task Force (USPSTF), clinicians should offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to patients at high risk of HIV acquisition (Grade A recommendation).
Emgality Approved to Treat Episodic Cluster Headache in Adults
The FDA has approved Emgality (galcanezumab-gnlm; Lilly) for injection for the treatment of episodic cluster headache in adults.
FDA to Review Triple Combination Tablet for Type 2 Diabetes
The FDA has accepted for review the New Drug Application for an investigational triple combination tablet for the treatment of adults with type 2 diabetes.
Xofluza Prevents Influenza in Those Living With an Infected Household Member
Individuals treated preventively with Xofluza were significantly less likely to develop influenza after exposure to an infected household member, according to data from the phase 3 BLOCKSTONE study.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...